

TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028

<https://marketpublishers.com/r/TCE6BD4C0CB6EN.html>

Date: July 2022

Pages: 111

Price: US\$ 3,000.00 (Single User License)

ID: TCE6BD4C0CB6EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028 Report Highlights:

Insight on Emerging TIM3 Inhibitors in Development As Monotherapy & combination Therapy

Future Market Opportunity Insight From First Drug Approval: 2024 - 2028

Insight On TIM3 Inhibitors Drug In clinical Trials: > 15 Drugs

TIM3 Inhibitors Drug In Clinical Trials Insight By Country, Company, Indication

Comprehensive Clinical Insight On Biomarker Identified During Clinical Trials

TIM3 Targeted Therapy Application By Various Cancers

Cancer immunotherapy is novel approach which harnesses the potential of immune system to target tumor cells. Subsequently, the entrance of immune checkpoint including cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) and its ligand (PD-L1) have shown huge potential in the treatment of cancer. However, despite these promising long-term responses, the majority of patients failed to respond to immune checkpoint blockade, demonstrating primary resistance. Additionally, many of these patients who initially respond to treatment eventually experience relapse secondary to acquired resistance. Recent studies have identified

several new immune checkpoint targets, like lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), T cell immunoglobulin and ITIM domain (TIGIT), V-domain Ig suppressor of T cell activation (VISTA), and so on.

More recently TIM3 has emerged as potential immune checkpoint inhibitor in the management of cancer. TIM-3 is regulatory of both innate and adaptive immune response and is expressed on multiple tumor types including effector T cells, monocytes, natural killer cells, and dendritic cells. Apart from this, TIM-3 has been shown to promote immune tolerance, and overexpression of TIM-3 is associated with more advanced stage and poor prognosis of disease. Owing to this, pharmaceutical companies have designed novel TIM-3 inhibitors across wide range of cancers.

The promising preclinical data has encouraged pharmaceutical companies to develop clinical pipeline of monoclonal antibodies targeting TIM-3 as an alternate to target cancers. Currently, several anti-TIM-3 monoclonal antibodies have been developed which have shown encouraging response in clinical trials. However, studies have supported the fact that combined blockade of PD-1 and TIM-3 pathways synergistically improved the CD8 T cell response and viral control. The advancement in the field of biotechnology and their encouraging response in combination therapy have led to development of bispecific antibodies. Currently, only a few bispecific antibodies have been developed, however with the advancement in the field of genetic engineering, it is expected that bispecific antibodies will emerge as shining star in TIM-3 therapy owing to several benefits associated with them.

The pipeline for novel TIM-3 inhibitors is highly concentrated and is expected to flourish in market during the forthcoming years. Cobolimab developed by Tesaro Therapeutics is one of the advanced stage TIM-3 inhibitors which are currently being evaluated in phase-II clinical trial. Recent data has shown that anti-TIM-3 antibody cobolimab is well-tolerated as monotherapy and in combination with the PD-1 inhibitor dostarlimab. Based on this encouraging data, company is translating the drug into late stage clinical trials for the management of solid tumors. Apart from this, several others drugs are under development including MBG453, Sym-023, BMS-986258, AZD7789, INCAGN02390, and others which are also present in initial stages of clinical development.

US is currently dominating the global market development for TIM3 Drugs driven by large number of ongoing clinical trials and presence of pharmaceutical companies which actively invest in this segment. Apart from this, US FDA also grants several special designations to expedite the drug development and approval process. For instance in

2021, US FDA granted fast track designation for sabatolimab (MBG453) for the treatment of adult patients with myelodysplastic syndromes (MDS) in combination with hypomethylating agents.

The global TIM-3 inhibitor market is expected to surpass US\$ 1 Billion by 2028 driven by first drug approval expected to be launch by 2024. Surge in prevalence of cancer across geographies, high demand for targeted therapeutics for cancer management, development of favorable reimbursement policies, and rise in awareness of TIM-3 immune checkpoint inhibitors for the management of cancer due to positive results in combination therapy are the major factors boosting the growth of market. In addition, surge in geriatric population and increase in technological advancements in screening and diagnosing cancer will supplement the market growth during the forecast period.

Contents

1. TIM3 - EMERGING IMMUNE CHECKPOINT

1.1 Introduction to TIM3 Inhibitor

1.2 Structure & Biology of TIM3

2. TIM3 AS CANCER COMBINATION IMMUNOTHERAPY TARGET

3. EMERGING TIM3 INHIBITORS IN DEVELOPMENT

4. TIM3 INHIBITOR MECHANISM OF ACTION

4.1 General Mechanism

4.2 Sabatolimab Proposed Mechanism of Action

5. POTENTIAL OF TIM3 AS CANCER BIOMARKER

5.1 TIM3 as Diagnostic Biomarker

5.2 TIM3 as Prognostic Biomarker

6. TIM3 THERAPY TARGETED THERAPEUTIC APPROACH

6.1 Small Molecule Immunotherapy

6.2 Monoclonal Antibodies

6.3 Bispecific Antibodies

7. GLOBAL TIM3 INHIBITORS DRUGS CLINICAL TRIALS OVERVIEW

7.1 By Company

7.2 By Country

7.3 By Patient Segment/Disease Stage

7.4 By Phase

8. GLOBAL TIM3 INHIBITORS DRUGS CLINICAL TRIALS BY COMPANY, INDICATION & PHASE

8.1 Preclinical

8.2 Phase-I

8.3 Phase-I/II

8.4 Phase-II

8.5 Phase-II/III

8.6 Phase-III

9. APPLICATION OF TIM3 TARGETED THERAPY IN CANCER

9.1 Myeloid Leukemia

9.2 Melanoma

9.3 Lung Cancer

9.4 Head & Neck Cancer

10. TIM3 THERAPY FUTURE PERSPECTIVE

10.1 Clinical Forecast

10.2 Future Market Opportunity

11. COMPETITIVE LANDSCAPE

11.1 Agenus

11.2 AstraZeneca

11.3 Aurigene

11.4 BeiGene

11.5 BrightPath Therapeutics

11.6 Bristol Myers Squibb

11.7 Chia Tai Tianqing Pharmaceutical Group

11.8 Curis

11.9 Eli Lilly

11.10 GlaxoSmithKline

11.11 HanAll Biopharma

11.12 Incyte Corporation

11.13 Ligand Pharmaceuticals

11.14 Neologics Bio

11.15 Novartis

11.16 Roche

11.17 Sutro Biopharma

11.18 Symphogen

11.19 TrueBinding

List Of Figures

LIST OF FIGURES

Figure 1-1: Structure of TIM-3

Figure 4-1: Mechanism of Action of Anti-TIM-3 Antibodies

Figure 4-2: Sabatolimab – Mechanism of Action

Figure 7-1: Global - Number of TIM3 Inhibitors Drugs in Clinical Trials by Company, 2022 till 2028

Figure 7-2: Global - Number of TIM3 Inhibitors Drugs in Clinical Trials by Country, 2022 till 2028

Figure 7-3: Global - Number of TIM3 Inhibitors Drugs in Clinical Trials by Disease Stage, 2022 till 2028

Figure 7-4: Global - Number of TIM3 Inhibitors Drugs in Clinical Trials by Phase, 2022 till 2028

Figure 10-1: Global – TIM3 Inhibitor Market Opportunity by Approval Time (US\$ Million), 2024 – 2028

I would like to order

Product name: TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028

Product link: <https://marketpublishers.com/r/TCE6BD4C0CB6EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TCE6BD4C0CB6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970